A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2002
11/07/2002	US20020165242 Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
11/07/2002	US20020165241 Such as 4-((methyl-pyrimidin-2-ylamino)-methyl)-piperidine-1-carboxylic acid benzyl ester; useful for pain relief; treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, and stroke; N-methyl-D-aspartate (NMDA)
11/07/2002	US20020165238 Such as 1-(3-carboxypyridyl-2)-4-methyl-2- phenylpiperazine dihydrate; antidepressants
11/07/2002	US20020165235 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists
11/07/2002	US20020165234 Selective B3 adrenergic agonists
11/07/2002	US20020165230 Gamma-ketoacid dipeptides as inhibitors of caspase-3
11/07/2002	US20020165224 Use of y-hydroxybutyric acid amides in the treatment of drug addiction and in particular of alcoholism
11/07/2002	US20020165217 Combination treatment for anxiety and depression
11/07/2002	US20020165213 Estrogen induced neural stem cell increase
11/07/2002	US20020165203 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents
11/07/2002	US20020165200 Central nervous system disorders
11/07/2002	US20020165197 Administering adenosine receptor ligand
11/07/2002	US20020165186 Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/07/2002	US20020165155 Crystallization of IGF-1
11/07/2002	US20020165150 Amino acid sequence from certain regions of tissue growth factor-beta super family serine-threonine kinase receptors
11/07/2002	US20020165120 Mixture of eletriptan and glycoprotein inhibitor; headache therapy
11/07/2002	US20020164791 Primitive neural stem cells and method for differentiation of stem cells to neural cells
11/07/2002	US20020164789 Suppressing glial cell activation in central nervous system; obtain mammal with brain disorder, administer modulator of nervous system activity, evaluate for adjusstment in brain disorder
11/07/2002	US20020164767 DNA encoding the human serine protease C-E
11/07/2002	US20020164760 Catalytically active recombinant memapsin and methods of use thereof
11/07/2002	US20020164738 Cell death inhibitory protein
11/07/2002	US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002	US20020164692 Immune system-related polynucleotides, polypeptides, and antibodies
11/07/2002	US20020164682 Mammalian cerberus-like protein and compositions
11/07/2002	US20020164668 Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
11/07/2002	US20020164373 Opioid sustained-released formulation
11/07/2002	US20020164352 Dietetics; anticholesterol agents; antidiabetic agents
11/07/2002	US20020164349 Induction apoptosis; west nile virus therapy
11/07/2002	US20020164314 Therapy for nervous system disorders
11/07/2002	US20020164312 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/07/2002	US20020164308 Embryonic stem cells and neural progenitor cells derived therefrom
11/07/2002	US20020164303 Administering nucleic acids to muscle tissue
11/07/2002	US20020164287 Azo compounds for type i phototherapy
11/07/2002	DE10120834A1 Neue Schmerzmittel, die Inhibitoren von TRP-Kanälen sind New painkillers that are inhibitors of TRP channels are
11/07/2002	DE10119863A1 Verwendung von Desoxypeganin zur Behandlung von psychiatrischen oder zerebralen Krankheitserscheinungen Use of deoxypeganine for the treatment of psychiatric or cerebral symptoms
11/07/2002	DE10119862A1 Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen Use of galantamine for the treatment of symptoms of disease of the central nervous system due to intoxication with psychotropic substances
11/07/2002	CA2744115A1 Carbonic anhydrase activators for enhancing learning and memory
11/07/2002	CA2601222A1 Once-a-day oxycodone formulations
11/07/2002	CA2594883A1 Pharmaceutically active uridine esters
11/07/2002	CA2454276A1 Neural progenitor cells
11/07/2002	CA2446514A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
11/07/2002	CA2446497A1 Crf receptor antagonists
11/07/2002	CA2445861A1 Pharmaceutically active uridine esters
11/07/2002	CA2445859A1 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene
11/07/2002	CA2445843A1 The use of enantiomeric pure escitalopram
11/07/2002	CA2445826A1 Treatment and diagnosis of macrophage mediated disease
11/07/2002	CA2445702A1 Control of compactability through crystallization
11/07/2002	CA2445629A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
11/07/2002	CA2445583A1 Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7h-[1,4]dioxino[2,3-e]indole
11/07/2002	CA2445581A1 Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoxaline
11/07/2002	CA2445568A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	CA2445565A1 Compositions and methods of double-targeting virus infections and cancer cells
11/07/2002	CA2445552A1 Antidepressant (sssri) azaheterocyclymethyl derivatives of 7,8-dihydro-3h-t,9-dioxa-1,3-diazacyclopenta[a]naphthalene
11/07/2002	CA2445543A1 Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-¬1,4\|-benzodioxans
11/07/2002	CA2445528A1 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
11/07/2002	CA2445376A1 Substance rkb-3564 having angiogenesis inhibitory action
11/07/2002	CA2445357A1 Pyrazole derived kinase inhibitors
11/07/2002	CA2445343A1 Use of protein and essential amino acids to treat amenorrhea and related disorders
11/07/2002	CA2445338A1 G-protein coupled receptors
11/07/2002	CA2445330A1 Potassium channel opener
11/07/2002	CA2445294A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
11/07/2002	CA2445290A1 A pharmaceutical tablet having a high api content
11/07/2002	CA2444911A1 Fusion molecules and methods for treatment of immune diseases
11/07/2002	CA2444882A1 Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
11/07/2002	CA2444436A1 Dual inhibitors of pde 7 and pde 4
11/07/2002	CA2443835A1 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	CA2440775A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
11/07/2002	CA2439943A1 Benzimidazoles that are useful in treating sexual dysfunction
11/07/2002	CA2408369A1 Substituted indoles as parp inhibitors
11/06/2002	WO2001084962A2 Compositions containing folic acid and reduced folate
11/06/2002	EP1255112A2 Treatment of T-cell mediated diseases
11/06/2002	EP1254905A1 4-(2-Pyridyl)piperazines having 5HT7 receptor agonist activity
11/06/2002	EP1254904A1 Novel piperidine compounds and drugs containing the same
11/06/2002	EP1254898A1 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
11/06/2002	EP1254668A2 Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
11/06/2002	EP1254662A2 Methods and kits for treating depression or preventing deterioration of cognitive function
11/06/2002	EP1254661A1 Method for preventing dyskinesias with selective NMDA-Antagonists
11/06/2002	EP1254660A2 Methods, kits and compositions for using pyrrole derivatives against anxiety
11/06/2002	EP1254659A1 Stable emulsion compositions
11/06/2002	EP1254658A1 Remedies
11/06/2002	EP1254270A1 Methods and materials relating to cub domain polypeptides and polynucleotides
11/06/2002	EP1254268A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
11/06/2002	EP1254266A1 Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides
11/06/2002	EP1254251A2 Neurosteroids as markers for alzheimer's disease
11/06/2002	EP1254242A1 17 human secreted proteins
11/06/2002	EP1254241A2 Phosphatases
11/06/2002	EP1254235A2 Drug metabolizing enzymes
11/06/2002	EP1254231A1 Genes encoding abc1 paralogs and the polypeptides derived therefrom
11/06/2002	EP1254224A2 Interferon-alpha induced genes
11/06/2002	EP1254222A1 Human gaba receptor proteins and polynucleotides encoding the same
11/06/2002	EP1254220A1 Human g-protein coupled 7 transmembrane receptor and polynucleotides encoding the same
11/06/2002	EP1254214A2 Human protein kinases and protein kinase-like enzymes
11/06/2002	EP1254212A2 Methods of preparing and using a viral vector library
11/06/2002	EP1254139A1 4-heteroaryl-1,4-diazabicyclo 3.2.2]nonane, preparation and therapeutic use thereof
11/06/2002	EP1254138A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
11/06/2002	EP1254134A2 1,3-dihydro-2h-indol-2-one derivatives,and their use as ligands for v1b or v1b and v1a arginine-vasopressin-receptors
11/06/2002	EP1254133A2 Indol-3-yl derivatives
11/06/2002	EP1254131A1 Extraction of flavonoids
11/06/2002	EP1254130A1 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
11/06/2002	EP1254123A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors

1 ... 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 ... 1833